On the heals of the Abbott – St. Jude deal, should Boston Scientific go in a completely different direction? What other medtech M&A deals should come to fruition? And how can medical device companies compete in the new era of bundled, value-based programs? These are just some of the topics covered in the latest edition of the Medsider newsletter. Enjoy…
Should Boston Scientific zag while other zig?
A Frost and Sullivan analyst speculates on what Boston Scientific should do given that two of its main competitors have engaged in mega-mergers.
4 medical device M&A deals I’d like to see
In the wake of the Abbott – St. Jude M&A deal, and the belief that the consolidation trend will continue, here are a few thoughts on some deals I’d like to see this year.
Hospitals to shift the cost pressure of hip and knee implants to medical device makers
Medical device makers, not hospitals, will get squeezed in the coming years as the Centers for Medicare and Medicaid (CMS) implements its value-based pricing scheme for hip and knee implant procedures.
Biotronik President: We are the best-kept secret in CRM
Marlou Janssen calls Biotronik the best-kept secret in cardiac rhythm management. In this Q&A, she reveals the new technologies that will change that.
5 tips on how to compete in a bundled care environment
Bundled payments in orthopedics represent an opportunity for smart medical device companies that are not afraid to change how they do business.
After selling 2 cardiovascular companies for over $1 billion, Duke Rohlen is now hoping to do the same with Spirox and Advanced Catheter Therapeutics
In this interview with Duke Rohlen, we learn about the strategies he employed that led to the successful exits of FoxHollow Technologies and CV Ingenuity for a combined total of over $800 million.
Until the next issue of the Medsider newsletter, cheers!